skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

14 Total results for product and free and sample content found

Scrip

IDMA Meet: Trump, Protectionism, New Markets And Cricket

By Anju Ghangurde 23 Jan 2017

The Trump presidency and the threat of protectionism, new generic opportunities beyond the US market, and the need for new quality benchmarks were some of the key issues discussed at the recent annual day celebrations of the Indian Drug Manufacturers’ Association.

Topics Strategy US election

Pink Sheet

Trump Takes Office, Change At US FDA Arrives With ‘Beachhead Teams’

By derrick-gingery 19 Jan 2017

Incoming president not holding over any FDA political appointees from the Obama administration, but what exactly his stamp on the agency will be remains unclear.

Topics US election FDA

Scrip

The Bully Pulpit: Trump Versus Drug Prices

By Michael McCaughan 18 Jan 2017

Medicare price negotiation is not a new idea – nor is the concept of using the Presidential megaphone to talk down drug prices. Will Trump and Twitter turn it into something bigger?

Topics US election

Pink Sheet

The Trump Administration: Seven More Things To Watch Out For

By Emily Hayes 11 Jan 2017

Beyond pricing, industry experts weigh in on how the next administration has shifted expectations across a range of areas – including tax reform, FDA standards and the Cancer Moonshot Initiative.

Topics US election

Scrip

Trump’s Rx For The Drug Industry: Take Two And Have No Idea What Will Happen In The Morning

By M. Nielsen Hobbs 12 Dec 2016

To call the incoming US president unpredictable would be an understatement, but that doesn’t mean that industry shouldn’t know what to expect.

Topics US election BioPharmaceutical Policy and regulation

Medtech Insight

The Unlikely Savior Of 21st Century Cures: Donald Trump

By Cole Werble 09 Dec 2016

The 21st Century Cures bill made it through the US Congress in 2016 after all; advocates can thank the unexpected presidential victory of Donald Trump for helping to make that happen.

Topics US election Policy and regulation

Pink Sheet

Possible Trump FDA Commish Candidate Favors (Much) Lighter Touch

By ferdous-al-faruque 08 Dec 2016

im O'Neill, a Silicon Valley investment manager, would be an unusual choice to head US FDA, not just because he isn’t a physician, but because he’s favored substantially reducing FDA's role in assessing product effectiveness.

Topics US election Policy and regulation

Scrip

Trump Win Is False Security For Drug Makers, Allergan CEO Warns

By Jessica Merrill 01 Dec 2016

Industry should act on drug pricing now while there is a post-election reprieve, Allergan CEO Brent Saunders said during the Forbes Healthcare Summit. Trump is a populist who will jump on the next big pricing scandal, he said.

Topics BioPharmaceutical US election

Pink Sheet

Trump’s ACA Repeal: What’s In It For Biopharma?

By cathy-kelly 15 Nov 2016

Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.

Topics US election Reimbursement

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907

Or email us your inquiry, so we can provide you the best possible customer service:
Pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: